Search
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).
Eliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigationalThe results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.
Naphazoline
go.drugbank.com/drugs/DB06711ApprovedNaphazoline was first developed in 1942 as a nasal formulation for congestion[A176609].
Mixtures: Visine for Allergy With Antihistamine, Clear Eyes for Dry Eyes Plus Redness ReliefCategories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor AgonistsKetotifen
go.drugbank.com/drugs/DB00920ApprovedInvestigationalavailable and indicated as an add-on therapy for children with atopic asthma. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.
Categories: Antihistamines for Systemic UseMogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … [L4168] It was approved for the same indications in Canada in June 2022.
Categories: Chemokine Receptor Type 4 Interaction, Chemokine Receptor Type 4 InteractionsPefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalCasirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. … They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.
Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAs hypertension is a major risk factor for cardiovascular disease,[A7354] early management of hypertension has several implications on patients' survival rate and quality of life in the future. … therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for
Categories: Antihypertensive Agents Indicated for Hypertension, Angiotensin 2 Receptor BlockerOteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and little interaction with human cytochrome P450s.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.
Categories: Adenosine A2 Receptor Antagonists, Purinergic P1 Receptor Antagonists